NCT06371638View on ClinicalTrials.gov

Dexmedetomidine and Postoperative Cognitive Dysfunction (POCD)

PHASE4CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

January 7, 2024

Primary Completion Date

March 1, 2024

Study Completion Date

March 7, 2024

Conditions

Postoperative Cognitive DysfunctionPostoperative Pain

Interventions

DRUG

Dexmedetomidine

General anaesthesia for subjects in Group D was maintained by target-controlled infusion (TCI) dexmedetomidine (Dyck mode) with target plasma of 1 ng/ml

DRUG

Sevoflurane

General anaesthesia for subjects in Group I was maintained by inhalation anaesthesia using sevoflurane at 0.8% concentration.

Trial Locations (1)

80114

Prof. Ngoerah General Hospital, Denpasar

All Listed Sponsors

lead

Udayana University

OTHER

NCT06371638 - Dexmedetomidine and Postoperative Cognitive Dysfunction (POCD) | Biotech Hunter | Biotech Hunter